
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio Inc demonstrates a strong positive outlook due to its innovative therapeutic approach targeting serious immune-related diseases, supported by compelling clinical data and an attractive current valuation. The company’s lead candidate, GRI-0621, has shown improvement in key serum biomarkers related to fibrosis and effective lung function outcomes, indicating potential therapeutic benefits and favorable safety profiles. Additionally, ongoing valuation assessments suggest significant upside potential from its current share price, reflecting a balanced approach considering the inherent risks and rewards in the biotech sector.
Bears say
GRI Bio Inc reported a net loss of $3.4 million or EPS of $(1.28), which fell short of both internal estimates and consensus expectations, indicating financial underperformance. Furthermore, the company faces significant risks, including potential failures of its product candidates during clinical trials, regulatory approval challenges, and issues related to commercialization and reimbursement, which could further exacerbate its financial instability. Additionally, with both product candidates still in the early phases of development, the lengthy timelines and high unpredictability surrounding clinical trials add considerable uncertainty regarding future revenue generation and overall financial health.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares